Akwai Alamar Nasara A Rigakafin Cizon Sauro Ta Farko

GlaxoSmithKline

Kamfanin sarrafa magunguna na Birtaniya GlaxoSmithKline yana neman izinin sayar da allurar rigakafin cizon sauro da aka gwada a yawancin cututtukan yaran kasashen Africa.
Kamfanin sarrafa magunguna na Birtaniya GlaxoSmithKline yana neman izinin sayar da allurar rigakafin cizon sauro da aka gwada a yawancin cututtukan yaran kasashen Africa.

An sami allurar rigakafin da ake kira RTS,S bayan an dauki wata 18 ana bincike, kuma ya warkar da kusan rabin cututtukan cizon sauro a kananan yaran da aka gwada, kuma ya rage kusan kwata na cututtukan cikin manya.

Kamfanin da ta shafe shekaru talatin yana harhada magunguna yace saboda wannan sakamako, yasa yayi shirin mika takardar bukata ga kungiyar magunguna ta Turai (EMA) a shekara ta dubu biyu da goma sha hudu.

Kanfanin ya kara da cewa kungiyar lafiya ta duniya, wadda ke a Geneva, ta nuna cewa zata bada damar amfani da wannan magani RTS,S daga farkon shekara ta 2015 idan cibiyar magunguna ta Turai ta amince mata.

Zazzabin cizon sauro yana kashe mutane dubu dari a shekara, yawanci kananan yara a kasashe matalauta na Africa, kuma masanan kimiyya sunce samun allurar rigakafi mai karfi zata sa a kawar da shi.

Wani kokarin da aka yi a baya bai sami nasara ba domin an gane cewa maganin yana rage zafin cutar ne kawai da kashi talatin bisa dari amma ba warkar da ita baki daya ba.